Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell
analysis solutions company, today announced the appointment of
Philippe Busque, Ph.D. as Senior Vice President of Global Sales
& Services. In this newly created position, Dr. Busque will
lead an enhanced global sales organization encompassing all
customer facing functions worldwide, including sales, service, and
technical application support, building on the recently integrated
sales team that combines the original Cytek sales force with the
Amnis® and Guava® sales force.
“Philippe’s extensive global sales and marketing
experience as an executive at several life science companies,
including Johnson & Johnson, Sony Biotechnology, and BD
Biosciences, makes him an outstanding choice to lead our sales
organization. Prior to his experience in sales, Philippe was
trained as a scientist with a master’s degree in microbiology and
Ph.D. in Immunology, giving him insight into Cytek’s customers’
full solution needs,” commented Dr. Wenbin Jiang, CEO of Cytek.
Cytek’s acquisition of the Amnis and Guava
product lines from Luminex Corporation in February 2023 provided
the Company with expanded market access, new product development
opportunities, and operational synergies. To take advantage of
these expanded market and product development opportunities, Cytek
is reorganizing its Commercial function into two distinct
operations: the enhanced sales organization led by Dr. Busque, and
a new Platform organization, which will encompass marketing,
product roadmaps, and program management. The Company believes the
new structure will support the Company’s transition toward a
market-driven organization and to develop and sell cell analysis
solutions based on market-derived inputs. These market inputs will
shape Cytek’s research, new product, and applications development,
and its approach to interacting with customers.
In parallel with these enhancements, Cytek’s
Chief Commercial Officer, Todd Garland, is leaving Cytek for
another opportunity. “We appreciate Todd’s contributions in
building Cytek’s commercial team and helping shape this enhanced
sales organization, which, I believe, will enable Cytek to better
serve our customers, be more responsive to market signals,
accelerate our revenue growth and profitability, and increase our
market presence,” said Dr. Jiang. “Our sales teams are excited
about the combination of our commercial organizations and the
opportunities brought to us through the transition toward a
market-driven focus, which is another strong validation of our
commitment to delivering full cell analysis solutions to our
customers.”
About Cytek Biosciences, Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis
solutions company advancing the next generation of cell analysis
tools by delivering high-resolution, high-content and
high-sensitivity cell analysis utilizing its patented Full Spectrum
Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the
power of information within the entire spectrum of a fluorescent
signal to achieve a higher level of multiplexing with precision and
sensitivity. Cytek’s FSP platform includes its core instruments,
the Aurora and Northern Lights™ systems; its cell sorter, the
Aurora CS; the flow cytometer and imaging products under the Amnis®
and Guava® brands; and reagents, software and services to provide a
comprehensive and integrated suite of solutions for its customers.
Cytek is headquartered in Fremont, California with offices and
distribution channels across the globe. More information about the
company and its products is available at www.cytekbio.com.
Other than Cytek’s Northern Lights CLC system and certain
reagents for use therewith, which are available for clinical use in
countries where the regulatory approval has been obtained from the
local regulatory authorities, including China and the European
Union, Cytek’s products are for research use only and not for use
in diagnostic procedures.
Cytek, Full Spectrum Profiling, FSP, Northern Lights, Amnis and
Guava are trademarks of Cytek Biosciences, Inc.
In addition to filings with the Securities and Exchange
Commission (SEC), press releases, public conference calls and
webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn
page and corporate “X” (formerly Twitter) account as
channels of distribution of information about its company,
products, planned financial and other announcements, attendance at
upcoming investor and industry conferences and other matters. Such
information may be deemed material information and Cytek may use
these channels to comply with its disclosure obligations under
Regulation FD. Therefore, investors should monitor Cytek’s website,
LinkedIn page, and X account in addition to following its SEC
filings, news releases, public conference calls and webcasts.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
as contained in Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, which are subject to the “safe harbor” created by those
sections. All statements, other than statements of historical
facts, may be forward-looking statements. Forward-looking
statements generally can be identified by the use of
forward-looking terminology such as “may,” “might," "will,”
“should,” “expect,” “plan,” “anticipate,” “could,” “intend,”
“target,” “project,” “contemplate,” “believe,” “estimate,”
“predict,” “potential” or “continue” or the negatives of these
terms or variations of them or similar terminology, but the absence
of these words does not mean that a statement is not
forward-looking. These forward-looking statements include
statements regarding Cytek’s market and product development
opportunities and the anticipated benefits of the enhanced sales
organization, including Cytek’s ability to better serve its
customers, be more responsive to market signals, accelerate its
revenue growth and profitability, and increase its market presence.
These statements are based on management’s current expectations,
forecasts, beliefs, assumptions and information currently available
to management. These statements also deal with future events and
involve known and unknown risks, uncertainties and other factors
that may cause actual results, performance or achievements to be
materially different from the information expressed or implied by
these forward-looking statements. Factors that could cause actual
results to differ materially include risks and uncertainties such
as those relating to global economic and market conditions; Cytek’s
ability to recognize the anticipated benefits of the acquired flow
cytometry and imaging business; Cytek’s dependence on certain sole
and single source suppliers; competition; market acceptance of
Cytek’s current and potential products; Cytek’s ability to manage
the growth and complexity of its organization, maintain
relationships with customers and suppliers and retain key
employees; Cytek’s ability to maintain, protect and enhance its
intellectual property; and Cytek’s ability to continue to stay in
compliance with its material contractual obligations, applicable
laws and regulations. You should refer to the section entitled
“Risk Factors” set forth in Cytek’s Quarterly Report on Form 10-Q
filed with the SEC on August 8, 2023 and other filings Cytek makes
with the SEC from time to time for a discussion of important
factors that may cause actual results to differ materially from
those expressed or implied by Cytek’s forward-looking statements.
Although Cytek believes that the expectations reflected in the
forward-looking statements are reasonable, it cannot provide any
assurance that these expectations will prove to be correct nor can
it guarantee that the future results, levels of activity,
performance and events and circumstances reflected in the
forward-looking statements will be achieved or occur. The
forward-looking statements in this press release are based on
information available to Cytek as of the date hereof, and Cytek
disclaims any obligation to update any forward-looking statements
provided to reflect any change in its expectations or any change in
events, conditions, or circumstances on which any such statement is
based, except as required by law. These forward-looking statements
should not be relied upon as representing Cytek’s views as of any
date subsequent to the date of this press release.
Media Contact:Stephanie OlsenLages &
Associates(949) 453-8080stephanie@lages.com
Investor Contact:Paul GoodsonHead of Investor
RelationsCytek Biosciencespgoodson@cytekbio.com
Cytek Biosciences (NASDAQ:CTKB)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Cytek Biosciences (NASDAQ:CTKB)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024